Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma

Status:
NOT_YET_RECRUITING

Trial end date:
2029-02-01

Target enrollment:

Participant gender:

Evaluation of the efficacy and safety of TQB2825 injection compared to immunotherapy in the treatment of recurrent/refractory follicular lymphoma.

PHASE3

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Rituximab